MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/1440-1681.13046

Медицинская библиотека · Clinical and experimental pharmacology & physiology · 2018

Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome.

Zachwieja Jacek, Silska-Dittmar Magdalena, Żurowska Aleksandra, Drożyńska-Duklas Magdalena, Hyla-Klekot Lidia, Kucharska Grażyna, Stankiewicz Roman, Olszak-Szot Ilona, Drożdż Dorota, Moczulska Anna, Zwolińska Danuta, Medyńska Anna, Sikora Przemysław, Bieniaś Beata, Tkaczyk Marcin, Rogowska-Kalisz Anna, Ostalska-Nowicka Danuta

СтатьяПеревод в очереди

Аннотация

The aim of the study was a multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab (Rtx) in children with steroid-resistant nephrotic syndrome (SRNS) with particular emphasis on the possibility of permanent discontinuation or dose reduction of other immunosuppressive drugs such as glucocorticoids and cyclosporine A after 6 months of observation. The study group consisted of 30 children with idiopathic nephrotic syndrome, who were unresponsive to standard immunosuppressive treatment, and hospitalized in the years 2010-2017 in eight paediatric nephrology centres in Poland. The children were administered a single initial infusion of rituximab at the dose of 375 mg/m2 of the body surface area. Proteinuria, the daily supply of glucocorticoids, and cyclosporine were assessed at the moment of the start of the treatment and after 6 months since its commencement. Before Rtx therapy, complete remission was found in 13 patients (43%) and partial remission was found in 8 patients (26%). These numbers increased to 16 (53%) and 12 (40%), respectively. At the start of the treatment 23 patients (76.6%) were treated with cyclosporine A. After 6 months, this number decreased to 15 patients (35%). At the start of the treatment, 18 patients (60%) were treated with prednisone. After 6 months, this number decreased to 8 patients (44%). Children with SRNS may potentially benefit from Rtx treatment despite relative risk of side effects. The benefits may include reduction of proteinuria or reduction of other immunosuppressants.

Для цитирования: Zachwieja Jacek, Silska-Dittmar Magdalena, Żurowska Aleksandra, Drożyńska-Duklas Magdalena, Hyla-Klekot Lidia, Kucharska Grażyna, Stankiewicz Roman, Olszak-Szot Ilona, Drożdż Dorota, Moczulska Anna, Zwolińska Danuta, Medyńska Anna, Sikora Przemysław, Bieniaś Beata, Tkaczyk Marcin, Rogowska-Kalisz Anna, Ostalska-Nowicka Danuta. Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome.. Clinical and experimental pharmacology & physiology. 2018. DOI: 10.1111/1440-1681.13046.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.